Teva executive Richard Daniell proposes $856K sale
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
TEVA's Executive VP European Commercial, Richard Daniell, reported a proposed sale of 20,003 ordinary shares, with an aggregate market value of $856,154.84 and an approximate sale date of November 11, 2026. The shares are identified as acquired through a stock option exercise and sale for compensation. The reported prior-three-month activity includes a sale of 25,000 shares on November 9, 2026, for gross proceeds of $1,072,789.40.
Key Figures
Key Terms
STOCK OPTION EXERCISE AND SALE financial
AGGREGATE MARKET VALUE financial
GROSS PROCEEDS financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.